| CAS NO: | 1018899-04-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 424.94 |
|---|---|
| Formula | C21H25ClO5S |
| CAS No. | 1018899-04-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility(In vitro) | DMSO: 84 mg/mL (197.7 mM) |
| Water: <1 mg/mL | |
| Ethanol: 17 mg/mL (40.0 mM) | |
| Other info | Chemical Name: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol InChi Key: QKDRXGFQVGOQKS-CRSSMBPESA-N InChi Code: InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1 SMILES Code: O[C@@H]([C@@H]([C@H]([C@H](C1=CC=C(Cl)C(CC2=CC=C(OCC)C=C2)=C1)O3)O)O)[C@H]3SC |
| Synonyms | Zynquista; LP-80203; LX4211; LP 80203; LX-4211; LP80203; LX 4211 |
| In Vitro | In vitroactivity: LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively. |
|---|---|
| In Vivo | In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements. |
| Animal model | Male albino C57BL/6-Tyrc-Brd mice |
| Formulation & Dosage | Dissolved in aqueous 0.1% v/v Tween 80; 60 mg/kg; oral administration. |
| References | J Pharmacol Exp Ther. 2013 May;345(2):250-9; Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. |
m.cnreagent.com
